Early Detection Opportunity Alzeca focuses on imaging technologies for early detection of Alzheimer’s pathology, presenting a potential fit for partnerships with pharma companies aiming to optimize patient selection and monitoring in clinical trials.

MRI Contrast Innovation The company is developing an ADx MRI contrast agent as an alternative to PET, creating a potential sales angle with imaging centers, hospitals, and researchers seeking safer, more accessible early diagnostic tools.

Funding & Validation Supported by Cure Alzheimer’s Fund, Alzheimer’s Association, NIH, and grants to academic partners, indicating credibility and opportunities to collaborate on funded projects or joint grant proposals.

Early Stage Commercialization Revenue range ($10M-$25M) and small company size (2-10 employees) suggest a vendor with agility and potential for strategic partnerships, clinical trial supply arrangements, and pilot programs with larger biopharma or CROs.

Strategic Advisory Renowned Key Opinion Leaders and a scientific advisory board offer a pathway to co-develop pilot studies, advisory roles, and credibility-building collaborations with research institutions and technology partners.